Compare MXF & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXF | TLSI |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.5M | 250.0M |
| IPO Year | 1995 | 2020 |
| Metric | MXF | TLSI |
|---|---|---|
| Price | $20.17 | $3.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 35.8K | ★ 206.3K |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $45,151,000.00 |
| Revenue This Year | N/A | $17.65 |
| Revenue Next Year | N/A | $40.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $18.62 | $2.20 |
| 52 Week High | $23.00 | $7.95 |
| Indicator | MXF | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 30.68 |
| Support Level | $19.65 | $3.05 |
| Resistance Level | $22.37 | $3.68 |
| Average True Range (ATR) | 0.43 | 0.21 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 34.04 | 11.11 |
Mexico Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation. The fund seeks to achieve its objective through investment in securities, primary in equity, listed on the Mexican Stock Exchange. The company's portfolio of investments consists of investments in different sectors such as auto parts, airports, building materials, chemical products, consumer products, energy, food, and other sectors. The fund provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.